Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis.

Vascular endothelial growth factor (VEGF) and its two receptors, Fms-like tyrosine kinase 1 (Flt-1) (VEGFR-1) and KDR/Flk-1 (VEGFR-2), have been demonstrated to be an essential regulatory system for blood vessel formation in mammals. KDR is a major positive signal transducer for angiogenesis through its strong tyrosine kinase activity. Flt-1 has a unique biochemical activity, 10-fold higher affinity to VEGF, whereas much weaker tyrosine kinase activity compared with KDR. Recently, we and others have shown that Flt-1 has a negative regulatory function for physiological angiogenesis in the embryo, possibly with its strong VEGF-trapping activity. However, it is still open to question whether the tyrosine kinase of Flt-1 has any positive role in angiogenesis at adult stages. In this study, we examined whether Flt-1+ could be a positive signal transducer under certain pathological conditions, such as angiogenesis with tumors overexpressing a Flt-1-specific, VEGF-related ligand. Our results show clearly that murine Lewis lung carcinoma cells overexpressing placenta growth factor-2, an Flt-1-specific ligand, grew in wild-type mice much faster than in Flt-1 tyrosine kinase domain-deficient mice. Blood vessel formation in tumor tissue was higher in wild-type mice than in Flt-1 tyrosine kinase-deficient mice. On the other hand, the same carcinoma cells overexpressing VEGF showed no clear difference in the tumor growth rate between these two genotypes of mice. These results indicate that Flt-1 is a positive regulator using its tyrosine kinase under pathological conditions when the Flt-1-specific ligand is abnormally highly expressed. Thus, Flt-1 has a dual function in angiogenesis, acting in a positive or negative manner in different biological conditions.

[1]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[2]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. , 1999, The Journal of clinical investigation.

[3]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[4]  E. Kremmer,et al.  Mapping of the Sites for Ligand Binding and Receptor Dimerization at the Extracellular Domain of the Vascular Endothelial Growth Factor Receptor FLT-1* , 1997, The Journal of Biological Chemistry.

[5]  M. Shibuya,et al.  Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[6]  S. Itohara,et al.  Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. , 1998, Cancer research.

[7]  T. Noda,et al.  Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Winer,et al.  Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. , 1992, The Journal of clinical investigation.

[9]  K. Alitalo,et al.  Genomic Organization of the Mouse and Human Genes for Vascular Endothelial Growth Factor B (VEGF-B) and Characterization of a Second Splice Isoform* , 1996, The Journal of Biological Chemistry.

[10]  K. Alitalo,et al.  Endothelial receptor tyrosine kinases involved in angiogenesis , 1995, The Journal of cell biology.

[11]  W. Stetler-Stevenson,et al.  Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. , 1996, Cell.

[12]  K. Toda,et al.  Establishment and characterization of a tumorigenic murine vascular endothelial cell line (F-2). , 1990, Cancer research.

[13]  C. Rossi,et al.  Inhibition of gelatinase A (MMP‐2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma , 1999, International journal of cancer.

[14]  M. Shibuya,et al.  A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. , 1995, Oncogene.

[15]  K. Alitalo,et al.  Vascular endothelial growth factor B, a novel growth factor for endothelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Persico.  Placenta Growth Factor , 2001 .

[17]  G. Viglietto,et al.  Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[18]  K. Alitalo,et al.  Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. , 1996, The American journal of pathology.

[19]  W. Stetler-Stevenson,et al.  Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3 , 1996, Cell.

[20]  G. Breier,et al.  The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities , 1996, The Journal of Biological Chemistry.

[21]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[22]  R. Kendall,et al.  Specificity of vascular endothelial cell growth factor receptor ligand binding domains. , 1994, Biochemical and biophysical research communications.

[23]  M. Shibuya,et al.  The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-γ pathway and partially induces mitotic signals in NIH3T3 fibroblasts , 1997, Oncogene.

[24]  K. Plate,et al.  Expression and localization of placenta growth factor and PlGF receptors in human meningiomas , 1999, The Journal of pathology.

[25]  M. Shibuya,et al.  Structure and function of vascular endothelial growth factor receptor-1 and -2. , 1999, Current topics in microbiology and immunology.

[26]  D. Dimitrov,et al.  Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. , 1992, Biochemical and biophysical research communications.

[27]  M. Shibuya,et al.  VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells , 1999, Oncogene.

[28]  A. Mantovani,et al.  Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. , 1996, Blood.

[29]  Janet Rossant,et al.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.

[30]  M. Shibuya,et al.  Characterization of the Extracellular Domain in Vascular Endothelial Growth Factor Receptor‐1 (Flt‐1 Tyrosine Kinase) , 1997, Japanese journal of cancer research : Gann.

[31]  K. Alitalo,et al.  The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells , 1993, The Journal of experimental medicine.

[32]  M. Shibuya,et al.  The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLCgamma. , 1997, Biochemical and biophysical research communications.

[33]  M. Shibuya,et al.  Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors. , 1998, Gene.

[34]  M. Shibuya,et al.  A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). , 1994, Oncogene.

[35]  M. Shibuya,et al.  Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[37]  B. Olffson.  Vascular endothelial grouth facter B, a novel growth facter for endothelial cells , 1996 .

[38]  K. Shitara,et al.  Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. , 1998, Cancer research.

[39]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  E. Manseau,et al.  Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. , 1995, Cancer research.

[41]  M. Shibuya,et al.  Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. , 1990, Oncogene.

[42]  C. Marcelle,et al.  Two molecules related to the VEGF receptor are expressed in early endothelial cells during avian embryonic development , 1993, Mechanisms of Development.

[43]  K. Alitalo,et al.  Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. , 1998, The American journal of pathology.

[44]  J. Winer,et al.  Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. , 1994, The Journal of biological chemistry.

[45]  J. Rossant,et al.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.

[46]  H. Granger,et al.  Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[47]  M. Shibuya,et al.  Neuropilin-1 Is a Placenta Growth Factor-2 Receptor* , 1998, The Journal of Biological Chemistry.

[48]  D. Maglione.  Persico MG.Isolation of a human placenta cDNA coding for a potein related to the vascular premeability factor , 1991 .

[49]  N. Copeland,et al.  A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[50]  T. Quinn,et al.  Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. , 1993, Proceedings of the National Academy of Sciences of the United States of America.